Australian biotech HaemaLogiX was awarded the Most Promising CAR-T Pipeline in APAC at the Asia Pacific CGT (Cell and Gene Therapy) Excellence Awards 2025, held last night in conjunction with the 9th Annual Cell & Gene Therapy World Asia 2025, in Singapore.
HaemaLogiX wins Most Promising CAR-T Pipeline
The award recognises companies demonstrating outstanding innovation, scientific excellence, and translational potential in the rapidly evolving CAR T therapy sector.
This accolade highlights HaemaLogiX’s role as a leader in advancing CAR T-cell therapies that have the potential to transform outcomes for patients with multiple myeloma across Asia Pacific and beyond.
“This award is a wonderful recognition of not just our science, but also the dedication and vision that drives our work,” noted Rosanne Dunn, Founder and Chief Scientific Officer of HaemaLogiX.
“We’re honoured to be recognised in such exceptional company – a field of the region’s top innovators – all striving to redefine what’s possible in CAR T-cell therapy. We’re more determined than ever to advance transformative therapies, particularly for multiple myeloma – the world’s second largest blood cancer and a disease for which there is currently no cure,” Dunn added.
Multiple myeloma
Multiple myeloma, a malignant disorder of plasma cells within the bone marrow, is the world’s second most common blood cancer.
Approximately 188,000 new cases are diagnosed globally each year, and approximately 60% of patients fail standard-of-care and progress to subsequent lines of therapy with poorer outcomes, with ~42% of patients not living more than five years past diagnosis.
Multiple myeloma is most common in older people. Less than 1% of these cancers are diagnosed in people younger than 35. Most people diagnosed with multiple myeloma are at least 65 years old. The average age of people diagnosed is 69.[1]
This underscores the significant unmet medical need for safer, more efficacious treatment options.
Science
HaemaLogiX’s immunotherapies bind to unexploited and unique targets (antigens) on the surface of cancerous plasma cells. These antigens, called kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA), are not present on normal plasma cells. This provides on-target efficacy and reduced off-tumour toxicity, thus preserving immune function and offering a key differentiation to current treatment options.
Approximately 70% of multiple myeloma patients are kappa-type and would express KMA, and 30% are lambda-type and would express LMA on their myeloma plasma cells. Multiple myeloma patients only express one or the other antigen on their myeloma plasma cells.
__
Note: * Click here to watch the exclusive interview with HaemaLigiX
Reference
[1] Key Statistics About Multiple Myeloma. American Cancer Society. Online. Last accessed on September 9, 2025.
Featured image: HaemaLogiX’s Professor Rosanne Dunn accepting an award at last night’s Asia Pacific Cell & Gene Therapy Excellence Awards 2025. Photo courtesy © 2025 HaemaLogiX. Used with permission.
DOI
